Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Thapsigargin Prodrug G-202 in Treating Patients with Recurrent or Progressive Glioblastoma

Trial Status: complete

This phase II trial studies how well thapsigargin prodrug G-202 works in treating patients with glioblastoma that has come back (recurrent) or is growing, spreading, or getting worse (progressive). Thapsigargin prodrug G-202 may shrink or slow down the growth of tumor cells by preventing nutrient and blood supply to tumor cells.